(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

ILLUCCYM

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

ILLUCCYM

ST13

US500000079296808

Class

5, 10

Filing

79296808

Registration

6549613

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

28

Latest update

07/30/2026

Trademark type

Word

Nice classes

5, 10

Filing date

08/27/2020

Registration date

11/09/2021

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

11/09/2021

Last transaction

07/30/2026

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Drawing code

4

Owner type

99

Owner location

AU

Examiner

LIEBL, ALEXANDRA

Law office

N20

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

Telix Pharmaceuticals Limited

Representatives

Andrew S. Ehard Merchant & Gould P.C.

Technical classification

Nice Classes

Class 5Class 10

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Chemical preparations for pharmaceutical purposesdiagnostic radiopharmaceutical preparations; pharmaceutical preparations for the imagingdiagnosing and monitoring of cancer; pharmaceutical preparations for the treatment of cancer; radiopharmaceutical imaging and detection agents for use in the imagingdiagnosing and monitoring of cancer

Class 10

Medical apparatusinfusion and injection devices for administering drugs and diagnostic radiopharmaceuticals; apparatus for medical purposesdrug delivery devices sold empty for diagnostic radiopharmaceuticalssyringes and infusion sets; medical devices for treating cancer; electromagneticradiological and nuclear medicine diagnostic imaging apparatus for medical use

Publications

History of USPTO decisions and trademark events.

28 publications found

NREP

NEW REPRESENTATIVE AT IB RECEIVED

07/30/2026

NREP

NEW REPRESENTATIVE AT IB RECEIVED

02/26/2026

NREP

NEW REPRESENTATIVE AT IB RECEIVED

08/14/2022

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

05/24/2022

FICS

FINAL DISPOSITION NOTICE SENT TO IB

04/28/2022

FIMP

FINAL DISPOSITION PROCESSED

04/28/2022

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

02/09/2022

R.PR

REGISTERED-PRINCIPAL REGISTER

11/09/2021

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

08/24/2021

PUBO

PUBLISHED FOR OPPOSITION

08/24/2021

GPNX

NOTIFICATION PROCESSED BY IB

08/22/2021

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

08/04/2021

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

08/04/2021

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

08/04/2021

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

07/20/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

07/16/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

07/16/2021

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

07/16/2021

RFNT

REFUSAL PROCESSED BY IB

02/07/2021

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

01/20/2021

RFRR

REFUSAL PROCESSED BY MPU

01/20/2021

MAFR

APPLICATION FILING RECEIPT MAILED

01/05/2021

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

12/31/2020

CNRT

NON-FINAL ACTION WRITTEN

12/30/2020

DOCK

ASSIGNED TO EXAMINER

12/30/2020

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

12/30/2020

LIMI

LIMITATION FROM ORIGINAL APPLICATION ENTERED

12/23/2020

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

10/29/2020

Continuous trademark protection

Get notified about every new filing that threatens ILLUCCYM or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.